Clinical Pharmacokinetics and Safety of a New HIV-1 Capsid Inhibitor, VH4004280, After Oral Administration in Adults Without HIV
Authors:
Open Access
- 26 April 2025
- journal article
- research article
- Published by Springer Nature in Infectious Diseases and Therapy
- Vol. 14 (6) , 1313-1326
Abstract
Introduction The pharmacokinetics, drug–drug interaction potential, and safety of a new HIV-1 capsid inhibitor, VH4004280 (VH-280), are described in this first-time-in-human study. Methods This randomized, double-blind, placebo-controlled, phase 1 study assessed oral VH-280 in adults without HIV. In parts 1 and 3, VH-280 was administered as powder-in-bottle (PiB) and tablet formulations, respectively, in single ascending doses. In part 2, VH-280 was administered as a PiB formulation once daily for 14 days in multiple ascending doses. In addition, in part 2, the effect of VH-280 on cytochrome P450 3A (CYP3A) activity was evaluated using midazolam as a probe substrate. Results In total, 73 participants were included (VH-280, n = 57; placebo, n = 16). Plasma exposures for VH-280 were broadly dose-proportional, and median time to maximum observed concentration was 9.0–17.0 h for the PiB and tablet formulations. Geometric mean terminal half-life was 145.8–207.8 h (> 6 days). Compared with PiB, exposures for the tablet formulation were 45–56% lower. Concomitant administration of midazolam after single and multiple doses of VH-280 did not result in clinically significant changes in midazolam or 1-hydroxymidazolam exposures; therefore, VH-280 is not anticipated to inhibit or induce CYP3A4. VH-280 was well-tolerated. Frequency of adverse events (AEs) was comparable between placebo and VH-280 groups. Adverse events related to VH-280 were primarily grade 1. There were no serious AEs, AEs leading to withdrawal from drug or study, or deaths. No trends in vital signs, electrocardiograms, or laboratory hematology parameters were observed, and there were no clinically relevant changes in chemistry parameters. Conclusions Data from this first-time-in-human study further characterize the pharmacokinetics of VH-280 after oral administration, providing support for the development of new capsid inhibitors as part of a complete long-acting regimen for the treatment and prevention of HIV-1. Clinical Trial Registration ClinicalTrials.gov, NCT05163522.Keywords
Funding Information
- ViiV Healthcare
This publication has 23 references indexed in Scilit:
- Twice-Yearly Lenacapavir for HIV Prevention in Men and Gender-Diverse PersonsNew England Journal of Medicine, 2025
- Twice-Yearly Lenacapavir or Daily F/TAF for HIV Prevention in Cisgender WomenNew England Journal of Medicine, 2024
- Efficacy, safety, and tolerability of switching to long-acting cabotegravir plus rilpivirine versus continuing fixed-dose bictegravir, emtricitabine, and tenofovir alafenamide in virologically suppressed adults with HIV, 12-month results (SOLAR): a randomised, open-label, phase 3b, non-inferiority trialThe Lancet HIV, 2023
- Efficacy and safety of the novel capsid inhibitor lenacapavir to treat multidrug-resistant HIV: week 52 results of a phase 2/3 trialThe Lancet HIV, 2023
- Antiretroviral Drugs for Treatment and Prevention of HIV Infection in AdultsJAMA, 2023
- Capsid Inhibition with Lenacapavir in Multidrug-Resistant HIV-1 InfectionNew England Journal of Medicine, 2022
- Cabotegravir for the prevention of HIV-1 in women: results from HPTN 084, a phase 3, randomised clinical trialThe Lancet, 2022
- Cabotegravir for HIV Prevention in Cisgender Men and Transgender WomenNew England Journal of Medicine, 2021
- Long-Acting Cabotegravir and Rilpivirine for Maintenance of HIV-1 SuppressionNew England Journal of Medicine, 2020
- Long-Acting Cabotegravir and Rilpivirine after Oral Induction for HIV-1 InfectionNew England Journal of Medicine, 2020